Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan

Cancer Research

Volumn 56, Issue 7, 1996, Pages 1664-1673

  Danks, Mary K ^a   Garrett, Katherine E ^a   Marion, Raquel C ^a   Whipple, David O ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AMSACRINE; CAMPTOTHECIN DERIVATIVE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; HOE 33342; HYDROXYUREA; MITOXANTRONE; TOPOTECAN; VINCRISTINE;

ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA PROTEIN COMPLEX; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; ENZYME LOCALIZATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DNA BINDING;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHILD; CYTOPLASM; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; MICROSCOPY, FLUORESCENCE; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0029862963     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Baker, S. D., Wadkins, R. M., Stewart, C. F., Beck, W. T., and Danks, M. K. Cell cycle analysis of amount of distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy Cytometry, 19: 134-145, 1995.
2. Fleischmann, G., Pflugfelder, G., Steiner, E. K., Javaherian, K., Howard, G. C. Wang, J. C., and Elgin, S. C. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc. Natl Acad. Sci. USA, 81: 6958-6962, 1984.
3. Muller, M T., Pfund, W. P., Mehta, V. B., and Trask, D. K. Eukaryoric type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO. J., 4: 1237-1243, 1985
4. Negri, C., Chiesa, R., Cerino, A., Bestagno, M , Sala, C., Zini, N., Maraldi, N. M., and Astaldi-Ricotti, G. C. B. Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II. 170- and 180-kDa isozymes. Exp. Cell Res., 200: 452-459, 1992.
5. Hsiang, Y-H., and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
6. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J Natl. Cancer Inst., 85: 271-291, 1993.
7. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst., 86: 836-842, 1994.
8. Sugimoto, Y., Tsukahara, S., Oh-hara, T., Isoe, T , and Tsuruo, T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50: 6925-6930, 1990.
9. Kubota, N., Kanzawa, F., Nishio, K., Takeda, Y., Ohmori, T., Fujiwara, Y., Terashima, Y., and Saijo, N. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem. Biophys. Res. Commun., 188: 571-577, 1992.
10. Benedetti, P., Fiorani, P., Capuani, L., and Wang, J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res., 53. 4343-4348, 1993
11. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y , and Pommier, Y. Mutation at the catalytic site of topoisomerase Iin CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55: 1339-1346, 1995.
12. Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J., and Johnson, R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res , 48. 6404-6410, 1988.
13. Rubin, E., Pantazis, P., Bharti, A., Toppmeyer, D., Giovanella, B., and Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitro-camptothecin. J. Biol. Chem., 269: 2433-2439, 1994.
14. D'Arpa, P., and Liu, L. F Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta, 989. 163-177, 1989.
15. Harker, W. G., Kapoor, R., Slade, D. L., Fujimori, A., and Pommier, Y Alterations in DNA topoisomerase I content and sensitivity in camptothecin-resistant human CEM leukemia cell lines. Proc. Am. Assoc. Cancer Res., 35: 456, 1994.
16. Beidler, D. R., and Cheng, Y-C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol. Pharmacol., 47: 907-914, 1995.
17. Zwelling, L A., Hinds, M., Chan, D., Mayes, J., Sie, K. L., Parker, E., Silberman, L., Radcliffe, A., Beran, M., and Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells: evidence for a drug-resistant form of topoisomerase II. J. Biol Chem., 264: 16411-16420, 1989.
18. Wolverton, J. S., Danks, M. K., Granzen, B., and Beck, W T. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Cancer Res., 52: 4248-4253, 1992.
19. Masters, B. R., and Kino, G. S. Charge-coupled devices for quantitative Nipkow disk real-time scanning confocal microscopy. In: D. Shotton (ed.), Electronic Light Microscopy, Chap. 14, pp. 315-327. New York: Wiley-Liss, 1993.
20. Castleman, K. R. Digital Image Processing. Englewood Cliffs, NJ: Prentice-Hall, 1979.
21. Borer, R. A., Lahner, C. F., Eppenberger, H. M., and Nigg, E A. Major nucleolar proteins shuttle between nucleus and cytoplasm Cell, 56: 379-390, 1989.
22. Zheng, C-F., and Guan, K-L. Cytoplasmic localization of the mitogen-activated protein kinase activator MEK. J. Biol. Chem., 269: 19947-19952, 1994.
23. Fernandes, D. F., Danks, M. K., and Beck, W. T Resistance to VM-26 is associated with selective decrease in nuclear matrix DNA topoisomerase II. Biochemistry, 29: 4235-4241, 1990.
24. Danks, M. K., Qiu, J , Catapano, C. V , Schmidt, C. A., Beck, W. T., and Fernandes, D. J. Subcellular distribution of the α and β topoisomerase II-DNA complexes stabilized by VM-26. Biochem. Pharmacol., 48: 1785-1796, 1994.
25. Yung, BY-M., Busch, H., and Chan, P-K. Effects of luzopeptins on protein B23 translocation and ribosomal RNA synthesis in HeLa cells. Cancer Res., 46: 922-925, 1986.
26. Chan, P-K , Aldrich, M B., and Yung, BY-M. Nucleolar protein B23 translocation after doxorubicin treatment in murine tumor cells. Cancer Res., 47: 3798-3801, 1987.
27. Zhang, H., Wang, J. C., and Liu, L. F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl Acad. Sci. USA, 85: 1060-1064, 1988.
28. Liu, L F., and Miller, K. G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl Acad. Sci. USA, 78: 3487-3491, 1981.
29. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J. Cancer Res., 84. 697-702, 1993
30. Kirshenbaum, M. R., Chen, S. F., Behrens, C H., Papp, L. M., Stafford, M. M , Sun, J. H., Behrens, D L., Fredericks, J. R., Polkus, S. T., Sipple, P., Patten, A. D., Dexter, D., Seitz, S. P., and Gross, J. L. (R,R)-2.2′-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis[5- nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione]dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro Cancer Res., 54: 2199-2206, 1994.
31. Chabner, B. A., and Collins, J. M Cancer Chemotherapy. Principles and Practice. New York: J. B. Lippincott Company, 1990
32. Chen, A. Y., Chiang, Y., Bodley, A., Peng, L. F , and Liu, L F A new mammalian DNA topoisomerase I poison Hoechst 33342, cytotoxicity and drug resistance in human cell cultures. Cancer Res., 53: 1332-1337, 1993.
33. Buckwalter, C. A., Lin, A. H., Tanizawa, A., Pommier, Y. G , Cheng, Y-C., and Kaufmann, S H. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I. Cancer Res., 56: 1674-1681, 1996.
34. Richardson, W. D., Mills, A D., Dilworth, S. M , Laskey, R. A., and Dingwall, C. Nuclear protein migration involves two steps, rapid binding at the nuclear envelope followed by slower translocation through nuclear pores. Cell, 52: 655-664, 1988.
35. Newmeyer, D D., and Forbes, D. J. Nuclear import can be separated into distinct steps in vitro: nuclear pore binding and translocation. Cell, 52. 641-653, 1988.